| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Articles |
The Wistar Institute [K. S., N. H. C., M. J. F. W., M. C. L., M. H., T. D. H.], and Departments of Genetics and Medicine, Howard Hughes Medical Institute, University of Pennsylvania [W. S. E.], Philadelphia, Pennsylvania 19104-4268
Abstract
Sporadic human tumors and the hereditary cancer predisposition syndrome Li-Fraumeni are frequently associated with mutations in the p53 tumor suppressor gene that compromise its ability to function as a DNA damage checkpoint. A subset of Li-Fraumeni patients with wild-type p53 alleles have mutations in chk2/hcds1, one of the genes signaling the presence of DNA damage to the p53 protein. This suggests that p53 may be kept inactive in human cancer by mutations targeting DNA damage signaling pathways. Melanoma cells are highly radioresistant, yet they express wild-type p53 protein, raising the possibility of defects in the pathways that activate p53 in response to DNA damage. We have described a chk2/hcds1-independent DNA damage signaling pathway that targets Ser-376 within the COOH terminus of p53 for dephosphorylation and leads to increased p53 functional activity. We now report that in several human melanoma cell lines that express wild-type p53, the phosphorylation state of Ser-376 was not regulated by DNA damage. In these cell lines, neither the endogenous wild-type p53 protein nor high levels of ectopic wild-type p53 led to cell cycle arrest or apoptosis. Thus, defective activation of p53 in response to DNA damage may underlie the radioresistance of human melanoma cells.
This article has been cited by other articles:
 |
|
 |
|
  K. A. Avery-Kiejda, X. D. Zhang, L. J. Adams, R. J. Scott, B. Vojtesek, D. P. Lane, and P. Hersey Small Molecular Weight Variants of p53 Are Expressed in Human Melanoma Cells and Are Induced by the DNA-Damaging Agent Cisplatin Clin. Cancer Res., March 15, 2008; 14(6): 1659 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. N. Ivanov, H. Zhou, and T. K. Hei Sequential Treatment by Ionizing Radiation and Sodium Arsenite Dramatically Accelerates TRAIL-Mediated Apoptosis of Human Melanoma Cells Cancer Res., June 1, 2007; 67(11): 5397 - 5407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S.M. Smalley, R. Contractor, N. K. Haass, A. N. Kulp, G. E. Atilla-Gokcumen, D. S. Williams, H. Bregman, K. T. Flaherty, M. S. Soengas, E. Meggers, et al. An Organometallic Protein Kinase Inhibitor Pharmacologically Activates p53 and Induces Apoptosis in Human Melanoma Cells Cancer Res., January 1, 2007; 67(1): 209 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Verhaegen, J. A. Bauer, C. Martin de la Vega, G. Wang, K. G. Wolter, J. C. Brenner, Z. Nikolovska-Coleska, A. Bengtson, R. Nair, J. T. Elder, et al. A Novel BH3 Mimetic Reveals a Mitogen-Activated Protein Kinase-Dependent Mechanism of Melanoma Cell Death Controlled by p53 and Reactive Oxygen Species Cancer Res., December 1, 2006; 66(23): 11348 - 11359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Monte, M. Simonatto, L. Y. Peche, D. R. Bublik, S. Gobessi, M. A. Pierotti, M. Rodolfo, and C. Schneider MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents PNAS, July 25, 2006; 103(30): 11160 - 11165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tovar, J. Rosinski, Z. Filipovic, B. Higgins, K. Kolinsky, H. Hilton, X. Zhao, B. T. Vu, W. Qing, K. Packman, et al. From the Cover: Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy PNAS, February 7, 2006; 103(6): 1888 - 1893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Bao and S. Stromblad Integrin {alpha}v-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen J. Cell Biol., November 22, 2004; 167(4): 745 - 756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bandyopadhyay, A. Mishra, and E. E. Medrano Overexpression of Histone Deacetylase 1 Confers Resistance to Sodium Butyrate-Mediated Apoptosis in Melanoma Cells through a p53-Mediated Pathway Cancer Res., November 1, 2004; 64(21): 7706 - 7710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. I. Amiri, L. W. Horton, B. J. LaFleur, J. A. Sosman, and A. Richmond Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition: Implication for Bortezomib (VELCADE, PS-341) as a Therapeutic Agent for Malignant Melanoma Cancer Res., July 15, 2004; 64(14): 4912 - 4918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Tang and E. A. Grimm Depletion of Endogenous Nitric Oxide Enhances Cisplatin-induced Apoptosis in a p53-dependent Manner in Melanoma Cell Lines J. Biol. Chem., January 2, 2004; 279(1): 288 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Herlyn, M. Padarathsingh, L. Chin, M. Hendrix, D. Becker, M. Nelson, Y. DeClerck, J. McCarthy, and S. Mohla New Approaches to the Biology of Melanoma: A Workshop of the National Institutes of Health Pathology B Study Section Am. J. Pathol., November 1, 2002; 161(5): 1949 - 1957. [Full Text] [PDF]
|
|
|
|
|
|
P. R. Nambiar, C. Giardina, K. Guda, W. Aizu, R. Raja, and D. W. Rosenberg Role of the Alternating Reading Frame (P19)-p53 Pathway in an in Vivo Murine Colon Tumor Model Cancer Res., July 1, 2002; 62(13): 3667 - 3674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Alarcon-Vargas and Z.'e. Ronai p53-Mdm2--the affair that never ends Carcinogenesis, April 1, 2002; 23(4): 541 - 547. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
